Open house Arzneimittelrabattverträge Bosutinib, ATC L01EA04
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Bosutinib, ATC L01EA04
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No guaranteed volume or minimum purchase; agreements are non-exclusive and may be superseded by other rebate contracts.
Complex submission requirements: paper copies must be received by specific deadlines, and electronic submissions requir...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Nov 2026
- Provision of Bosutinib (ATC L01EA04) under non-exclusive rebate agreements with AOK Bayern.
- Contracts are open to all interested pharmaceutical companies meeting eligibility criteria.
Show full summary
Open-house model for non-exclusive drug rebate agreements for Bosutinib (ATC L01EA04) with AOK Bayern. All interested pharmaceutical companies meeting eligibility can join. No competitive selection, no estimated value disclosed. Contract duration December 2024 to November 2026, with flexible entry until October 2026.
Risks
No guaranteed volume or minimum purchase; agreements are non-exclusive and may be superseded by other rebate contracts.
Complex submission requirements: paper copies must be received by specific deadlines, and electronic submissions requir...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company.
Administrative
- Submit signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
- Submit signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.
Requirements may be incomplete.
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Bosutinib, ATC L01EA04
Non-exclusive rebate agreements for Bosutinib. All eligible pharmaceutical companies can enter into identical, non-negotiable contracts. No competition, open to all who meet eligibility.
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 16 Oct 2024
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 628220-2024
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No guaranteed volume or minimum purchase; agreements are non-exclusive and may be superseded by other rebate contracts.
Complex submission requirements: paper copies must be received by specific deadlines, and electronic submissions requir...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications